Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEPCORLI: Peri-operative vs Postoperative XELOX for Colon Cancer with Liver Metastasis
NCT02912052Phase 3Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2016
- Primary completion
- Oct 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin and capecitabine in colon cancer (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Disease-Free Survival at 5 years. Status: unknown.
02
Drugs
oxaliplatincapecitabine
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02912052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912052.